Microbot Medical's LIBERTY System Gains Traction as Q2 Revenue Surpasses Q1
Event summary
- Microbot Medical recorded revenue in Q1 2026 from the Limited Market Release (LMR) of its LIBERTY System.
- Q2 2026 mid-quarter revenue has already exceeded total Q1 revenue, driven by a more than doubling of accounts since the end of LMR.
- The LIBERTY System is now adopted by hospitals in six states: Georgia, Florida, New York, Michigan, Massachusetts, and North Carolina.
- Boston became the first city with multiple accounts using the LIBERTY System, reflecting growing commercial momentum.
- The system has been used for a variety of procedures, including the world’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH).
The big picture
Microbot Medical's transition to commercial operations marks a significant milestone in the adoption of robotic endovascular technology. The company's ability to more than double its accounts and exceed Q1 revenue in mid-Q2 highlights the growing acceptance of the LIBERTY System. This momentum is supported by industry tailwinds and visibility at major conferences, positioning Microbot Medical for continued growth in the U.S. and potential international expansion.
What we're watching
- Commercial Momentum
- Whether Microbot Medical can sustain the current pace of account growth and revenue increase as it expands into new territories.
- Regulatory Tailwinds
- How updated guidelines on occupational radiation and musculoskeletal protection adopted by medical societies will impact the adoption of the LIBERTY System.
- International Expansion
- The pace at which Microbot Medical can build a global commercial infrastructure and penetrate international markets.
Related topics